Candel Therapeutics (CADL) EPS (Basic) (2020 - 2023)
Historic EPS (Basic) for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to -$0.38.
- Candel Therapeutics' EPS (Basic) fell 12352.94% to -$0.38 in Q4 2023 from the same period last year, while for Dec 2023 it was -$1.3, marking a year-over-year decrease of 10312.5%. This contributed to the annual value of -$1.74 for FY2024, which is 3282.44% down from last year.
- Latest data reveals that Candel Therapeutics reported EPS (Basic) of -$0.38 as of Q4 2023, which was down 12352.94% from -$0.29 recorded in Q3 2023.
- Candel Therapeutics' EPS (Basic)'s 5-year high stood at $0.51 during Q4 2021, with a 5-year trough of -$1.46 in Q2 2021.
- For the 4-year period, Candel Therapeutics' EPS (Basic) averaged around -$0.36, with its median value being -$0.3 (2022).
- Its EPS (Basic) has fluctuated over the past 5 years, first skyrocketed by 15666.67% in 2021, then crashed by 90000.0% in 2023.
- Quarter analysis of 4 years shows Candel Therapeutics' EPS (Basic) stood at -$0.9 in 2020, then surged by 156.67% to $0.51 in 2021, then tumbled by 133.33% to -$0.17 in 2022, then plummeted by 123.53% to -$0.38 in 2023.
- Its EPS (Basic) stands at -$0.38 for Q4 2023, versus -$0.29 for Q3 2023 and -$0.33 for Q2 2023.